NeuroOne to Announce Fiscal Year 2025 Financial Results and Corporate Update

NeuroOne Medical Technologies Corporation will release financial results for its fiscal fourth quarter and year ended September 30, 2025, before market open on December 17, 2025. The company, which focuses on improving surgical care options and outcomes for patients suffering from neurological disorders, will host an investor conference call and webcast at 8:30 a.m. Eastern time on Wednesday, December 17, 2025. Management will discuss the company's fourth quarter and full fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants.

The financial results announcement comes as NeuroOne continues developing and commercializing minimally invasive and hi-definition solutions for EEG recording, stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company's work in these areas aims to improve patient outcomes and reduce procedural costs, with potential applications extending to other medical conditions such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence.

Investors and interested parties can participate in the conference call using the provided dial-in numbers or access the webcast through the company's investor relations portal. The U.S. dial-in number is 888-506-0062, while international participants can call 973-528-0011, using participant access code 924910. The webcast will be available at the company's designated earnings call page, and participants are advised to join at least five minutes before the start of the call to ensure timely participation.

A playback of the call will be available through Wednesday, December 31, 2025, accessible by calling 877-481-4010 within the United States or 919-882-2331 internationally, using replay passcode 53302. The webcast replay will also be available through the same webcast link until December 31, 2025. This financial results announcement is significant as it provides stakeholders with critical information about NeuroOne's financial performance and strategic direction during a period of continued development in neurological treatment technologies.

The company's focus on neurological disorders addresses a significant medical need, with conditions like epilepsy and Parkinson's disease affecting millions worldwide. NeuroOne's approach to developing minimally invasive solutions represents an important advancement in treatment options that could potentially reduce healthcare costs while improving patient quality of life. The financial results will indicate the company's progress in commercializing these technologies and its ability to sustain research and development efforts in this competitive medical technology sector.

For additional information about the company and its technologies, interested parties can visit the corporate website at https://www.nmtc1.com. The original announcement of the earnings release schedule was made available through standard financial disclosure channels, ensuring transparency and timely information for the investment community following the company's activities in the neurological medical technology space.